MX9706130A - Uso de compuestos especificos de lck sh2 para tratar enfermedades autoinmunes y el rechazo de aloinjertos. - Google Patents

Uso de compuestos especificos de lck sh2 para tratar enfermedades autoinmunes y el rechazo de aloinjertos.

Info

Publication number
MX9706130A
MX9706130A MX9706130A MX9706130A MX9706130A MX 9706130 A MX9706130 A MX 9706130A MX 9706130 A MX9706130 A MX 9706130A MX 9706130 A MX9706130 A MX 9706130A MX 9706130 A MX9706130 A MX 9706130A
Authority
MX
Mexico
Prior art keywords
domain
human
lck
autoimmune diseases
binding affinity
Prior art date
Application number
MX9706130A
Other languages
English (en)
Other versions
MXPA97006130A (es
Inventor
Damien John Dunnington
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1996/001964 external-priority patent/WO1996024343A1/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9706130A publication Critical patent/MX9706130A/es
Publication of MXPA97006130A publication Critical patent/MXPA97006130A/es

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un método de tratamiento de enfermedades autoinmunes en un sujeto, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto que se une a un dominio de 1ck SH2 humano con una afinidad de union que es de mas de cincuenta veces mayor que la afinidad de union con la cual el compuesto se une a un dominio de src SH2 humano y un dominio de fyn SH2 humano, y se une a un dominio de hcp SH2 humano, un dominio de Grb2 SH2 humano, un dominio de SH-PTP2 SH2 humano y un dominio de p85 SH2 humano con una afinidad de union que es de más de cincuenta veces menor que la afinidad de union con la cual el compuesto se une a un dominio de 1ck SH2 humano.
MXPA/A/1997/006130A 1995-02-10 1997-08-11 Uso de compuestos especificos de lck sh2 para tratar enfermedades autoinmunes y el rechazo de aloinjertos MXPA97006130A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US386381 1995-02-10
PCT/US1996/001964 WO1996024343A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Publications (2)

Publication Number Publication Date
MX9706130A true MX9706130A (es) 1997-11-29
MXPA97006130A MXPA97006130A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
TR199700791T1 (xx) 1998-03-21
ZA961001B (en) 1996-08-13
ZA961000B (en) 1996-08-07

Similar Documents

Publication Publication Date Title
CA2146647A1 (en) Treatment of autoimmune and inflammatory disorders
CA2256413A1 (en) Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
GR3036347T3 (en) Compounds useful for treating allergic and inflammatory diseases.
EP0634930A4 (en) Compounds useful for treating allergic and inflammatory diseases.
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
IL115733A0 (en) Binding agents and their use for therapeutic treatment
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
AU682166B2 (en) Synergising association having an antagonist effect on NK1 and NK2 receptors
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
EP0728482A3 (en) Use of hcp specific compounds to enhance erythropoiesis
CA2316411A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
MX9706130A (es) Uso de compuestos especificos de lck sh2 para tratar enfermedades autoinmunes y el rechazo de aloinjertos.
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
EP0797994A3 (en) Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings
NO973659L (no) Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
WO1998001100A3 (en) Method for treating homozygous familial hypercholesterolemia
AU7750794A (en) Use of hydroxychloroquine for treatment of graft-versus-host disease
EP0791360A3 (en) Treatment of septic shock with anti-TNF antibodies
MY115415A (en) Medicaments.
CA2248753A1 (en) Use of olanzapine for treating excessive aggression
AU6829396A (en) Compositions and their uses